


PaceMate Gains Exclusive Access to PaceArt Device Data Following Acquisition from Medtronic

PaceMate is the Only Cardiac Monitoring Company With Comprehensive Access to Both Historical Device Data & SessionSync In-Clinic Device Checks for PaceArt Users



SARASOTA, FL, UNITED STATES, August 14, 2025 /EINPresswire.com/ --

[PaceMate](#), the cardiac remote monitoring and management platform that leading healthcare providers trust, has officially completed a year-long project, resulting in two new exclusive abilities. The company is now able to directly migrate all historical patient data from PaceArt Optima™ to [PaceMateLIVE](#). It is additionally the only company to integrate with SessionSync, the in-clinic data capture tool for Medtronic devices, and wirelessly transfer in-clinic patient data. Prior to making this new functionality live to the broader PaceArt user base, select healthcare providers gained early access to PaceMate's precision data transfer capabilities with great success.

PaceMate acquired PaceArt from Medtronic in 2024 and healthcare providers across the country have since transitioned from the legacy solution to PaceMate's cloud-based platform. As part of the acquisition, PaceMate also brought on the original Medtronic team, who have been critical to preparing both platforms for the new system-to-system data migration.

PaceMate is now the only company able to migrate comprehensive historical PaceArt patient data—including patient visit summaries, device advisory details, patient comments and historical manufacturer reports—directly to its platform. And it does so without risk of inaccuracies or missing data points. Similarly, PaceMate integrates with SessionSync In-Clinic Data Transfer, which enables it to wirelessly transfer all data from Medtronic device checks, rather than transferring limited data through a USB or manual data entry. This process results in clinics being able to manage routine patients in under 2 minutes, saving an average of 2.5 minutes per patient—or nearly 4.25 hours per 100 patients.

Healthcare providers that previously relied on PaceArt for cardiac monitoring are gaining more than just robust data access when they make the transition to PaceMateLIVE. They are now able to:

- Manage all cardiac devices from one unified platform. This includes more than 150 discrete data points from implantables, wearables, ambulatory, heart failure and consumer ECG devices—all in a single interface.
- Streamline workflows that have traditionally been spread across multiple different platforms.
- Prioritize critical patients through its proprietary Auto-Triage functionality, which automatically distinguishes between standard manufacturer alerts and truly actionable alerts that require priority attention from clinicians. They can also create customizable parameters that affect all patients—or apply only to individuals.
- Integrate with EHRs in real-time through a proven track record of over 700 completed integrations – the most in the industry.
- Receive real-time updates, including instant notifications on new features, critical advisories or recalls. This ensures healthcare providers can take immediate action to maintain patient safety.
- Optimize practice performance with analytics. Turn data into actionable insights that optimize practice performance, productivity and operational decisions.
- Automate billing to seamlessly manage clinic reimbursements.
- Offer deeper patient chronology, fuel research and accelerate machine learning outcomes.

“Since our acquisition of PaceArt Optima, we’ve been dedicated to servicing its users whether or not they migrate to PaceMateLIVE,” said J.R. Finkelmeier, CEO of PaceMate. “And because we’ve spent 10 years at the forefront of the industry’s evolution, we know that many healthcare systems are planning to switch to a cloud-based platform. Our plan is to continue supporting customers who want to remain on PaceArt, and we’re making it so that when they’re ready to switch to the cloud, they will be getting the best and most valuable experience available on the market.”

PaceMate’s comprehensive monitoring and data management platform scales with users’ growth and ensures undisrupted continuity of patient care.

For more information on why Medtronic chose PaceMate to service PaceArt customers and their future cardiac data workflow needs, please see [the acquisition press release here](#).

PaceMate currently serves more than 1,000 clinic locations and has more than 2 million patients under management. Now in its 11th year in business, PaceMate is focused on pairing a decade of product innovation with the operational scale needed to meet the evolving demands of modern cardiac care.

About PaceMate

PaceMate® is the always-on cardiac device management platform that leading clinicians trust to optimize their practices, prioritize critical patients and deliver better and faster care. The company’s cloud-based system enables care teams to manage cardiac device patients through a single, end-to-end platform that integrates with all EHRs. With always up-to-date,

comprehensive data, PaceMate delivers actionable insights for providers to optimize practice performance and drive better patient outcomes. PaceMate is helping integrated delivery networks (IDNs) and academic health systems, including Duke Health, Advocate Health and many others modernize and scale cardiac care delivery. The company is headquartered in Sarasota, Florida. Join us at [PaceMate.com](https://www.pacemate.com) to see how together—we never miss a beat.®

Kieran Powell

PaceMate

+1 212-680-0179

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/839499278>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.